The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Open accessAbstract
The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago. Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets. As a better understanding of MMP biology and inhibitor pharmacokinetic properties emerged, it became clear that initial MMP inhibitor clinical trials were held prematurely. Further complicating matters were problematic conclusions drawn from animal model studies. The most recent generation of MMP inhibitors have desirable selectivities and improved pharmacokinetics, resulting in improved toxicity profiles. Application of selective MMP inhibitors led to the conclusion that MMP-2, MMP-9, MMP-13, and MT1-MMP are not involved in musculoskeletal syndrome, a common side effect observed with broad spectrum MMP inhibitors. Specific activities within a single MMP can now be inhibited. Better definition of the roles of MMPs in immunological responses and inflammation will help inform clinic trials, and multiple studies indicate that modulating MMP activity can improve immunotherapy. There is a U.S. Food and Drug Administration (FDA)-approved MMP inhibitor for periodontal disease, and several MMP inhibitors are in clinic trials, targeting a variety of maladies including gastric cancer, diabetic foot ulcers, and multiple sclerosis. It is clearly time to move on from the dogma of viewing MMP inhibition as intractable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., & Werb, Z. (1998) · Cell · doi:10.1016/s0092-8674(00)81169-1 · Cited by 1,750
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Gehron Robey, P., Poole, A. R., Pidoux, I., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80064-1 · Cited by 1,298
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Metalloproteinases and Wound Healing
Caley, M. P., Martins, V. L. C., & O'Toole, E. A. (2015) · Advances in Wound Care · doi:10.1089/wound.2014.0581 · Cited by 986
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. H. (1999) · Chemical Reviews · doi:10.1021/cr9804543 · Cited by 982
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Cited by
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression
Niland, S., Riscanevo, A. X., & Eble, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010146 · Cited by 503
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
Mechanisms of assembly and remodelling of the extracellular matrix
Naba, A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00767-3 · Cited by 316
Rajeev, V., Fann, D. Y., Dinh, Q. N., Kim, H. A., De Silva, T. M., Lai, M. K. P., Chen, C. L.-H., Drummond, G. R., Sobey, C. G., & Arumugam, T. V. (2022) · Theranostics · doi:10.7150/thno.68304 · Cited by 296
Wang, P., Gong, Q., Hu, J., Li, X., & Zhang, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01704 · Cited by 270
Matrix Metalloproteinases on Skin Photoaging
Feng, C., Chen, X., Yin, X., Jiang, Y., & Zhao, C. (2024) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.16558 · Cited by 112
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
3D PCL/collagen nanofibrous medical dressing for one-time treatment of diabetic foot ulcers
Chang, T., Yin, H., Yu, X., Wang, L., Fan, L., Xin, J. H., & Yu, H. (2022) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112480 · Cited by 32
Metadata
- Authors
- Fields, G. B.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-08-27
- Volume
- 8
- Issue
- 9
- Pages
- 984
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2970104014
- Cited by
- 299
- References
- 198
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.